Myovant Sciences - Stock Price History | MYOV

Historical daily share price chart and data for Myovant Sciences since 2022 adjusted for splits. The latest closing stock price for Myovant Sciences as of August 15, 2022 is 18.40.
  • The all-time high Myovant Sciences stock closing price was 27.62 on December 31, 2020.
  • The Myovant Sciences 52-week high stock price is 27.43, which is 49.1% above the current share price.
  • The Myovant Sciences 52-week low stock price is 7.67, which is 58.3% below the current share price.
  • The average Myovant Sciences stock price for the last 52 weeks is 15.55.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Myovant Sciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 21.1945 24.8300 26.9900 14.3100 15.5700 -43.63%
2020 15.7647 14.7600 27.6200 6.5500 27.6200 77.96%
2019 13.1238 16.9300 25.0000 4.2000 15.5200 -5.42%
2018 19.8959 12.4600 26.7800 12.4600 16.4100 29.83%
2017 12.3598 11.8400 16.4000 9.9300 12.6400 1.61%
2016 11.5871 13.2600 14.2500 10.4500 12.4400 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.774B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00